The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of multiple sclerosis, published as a randomized controlled trial.

Who Took Part

The study group was 172 patients.

PubMed indexes the participants as teenagers, young adults, adults and middle-aged adults, both men and women.

Eligibility criteria include diagnosis of RRMS, age 18 to 50 years, and Expanded Disability Status Scale ≤4.0.

Disease duration and activity requirements depend on whether 2005 or 2010 criteria are used for diagnosis.

How the Study Was Run

The design is described as randomized and double-blind.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Enrollment is restricted based on prior MS therapy exposure and recent vitamin D use.

What Was Measured

The subject headings attached to it are Dietary Supplements, Glatiramer Acetate, Immunosuppressive Agents, Magnetic Resonance Imaging, Multiple Sclerosis, Relapsing-Remitting, Peptides and United States.

The authors tagged it with the keywords Clinical trial, Double-blind, Randomized and Vitamin D.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc in 172 patients in people with multiple sclerosis.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (Contemporary clinical trials), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Multiple sclerosis research.